Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors

Stem Cells

Volumn 23, Issue 2, 2005, Pages 220-229

  Sarugaser, Rahul ^a   Lickorish, David ^a   Baksh, Dolores ^a   Hosseini, M Morris ^a   Davies, John E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Allogeneic cells; Cryopreservation; Major histocompatibility complexes; Mesenchymal progenitors; Therapeutic dose; Umbilical cord

Indexed keywords

ALPHA ACTIN; CD34 ANTIGEN; CD45 ANTIGEN; CELL MARKER; DESMIN; HERMES ANTIGEN; PROTEIN SH2; THY 1 ANTIGEN; VIMENTIN;

ARTICLE; CELL CULTURE; CELL ISOLATION; CELL SURFACE; COLONY FORMING UNIT F; CRYOPRESERVATION; CULTURE MEDIUM; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; OSTEOBLAST; PERICYTE; PHENOTYPE; PROTEIN EXPRESSION; UMBILICAL CORD; UMBILICAL CORD PERIVASCULAR CELL;

CELL DIFFERENTIATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FIBROBLASTS; HUMANS; MESENCHYMAL STEM CELLS; OSTEOGENESIS; UMBILICAL CORD;

EID: 13744254666     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2004-0166     Document Type: Article

References (66)

1. Bach FH, Albertini RJ, Joo P et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968;2:1364-1366.
2. Krebsbach PH, Mankani MH, Satomura K et al. Repair of craniotomy defects using bone marrow stromal cells. Transplantation 1998;66:1272-1278.
3. Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385-386.
4. Muschler GF, Nitto H, Matsukura Y et al. Spine fusion using cell matrix composites enriched in bone marrow-derived cells. Clin Orthop 2003:102-118.
5. Wakitani S, Kimura T, Hirooka A et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Surg Br 1989;71:74-80.
6. Wakitani S, Imoto K, Yamamoto T et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002;10:199-206.
7. Ponticiello MS, Schinagl RM, Kadiyala S et al. Gelatin-based resorbable sponge as a carrier matrix for human mesenchymal stem cells in cartilage regeneration therapy. J Biomed Mater Res 2000;52:246-255.
8. Solchaga LA, Gao J, Dennis JE et al. Treatment of osteochondral defects with autologous bone marrow in a hyaluronan-based delivery vehicle. Tissue Eng 2002;8:333-347.
9. Young RG, Butler DL, Weber W et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 1998;16:406-413.
10. Awad HA, Butler DL, Boivin GP et al. Autologous mesenchymal stem cell-mediated repair of tendon. Tissue Eng 1999;5:267-277.
11. Awad HA, Butler DL, Harris MT et al. In vitro characterization of mesenchymal stem cell-seeded collagen scaffolds for tendon repair: effects of initial seeding density on contraction kinetics. J Biomed Mater Res 2000;51:233-240.
12. Murphy JM, Fink DJ, Hunziker EB et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-3474.
13. Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair theinfarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001;98:10344-10349.
14. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
15. Toma C, Pittenger MF, Cahill KS et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98.
16. Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003;361:45-46.
17. Stamm C, Kleine HD, Westphal B et al. CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg 2004;52:152-158.
18. Jeannet M, Speck B, Rubinstein A et al. Autologous marrow reconstitutions in severe aplastic anaemia after ALG pretreatment and HL-A semi-incompatible bone marrow cell transfusion. Acta Haematol 1976;55:129-139.
19. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37:30-42.
20. Fouillard L, Bensidhoum M, Bories D et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003;17:474-476.
21. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85-95.
22. Angelopoulou M, Novelli E, Grove JE et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003;31:413-420.
23. + human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 2004;103:3313-3319.
24. Koç ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
25. Van Damme A, Vanden Driessche T, Collen D et al. Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther 2002;2:195-209.
26. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
27. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
28. Hurd DD. Allogeneic and autologous bone marrow transplantation for acute nonlymphocytic leukemia. Semin Oncol 1987;14:407-415.
29. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.
30. Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920-926.
31. McElreavey KD, Irvine AI, Ennis KT et al. Isolation, culture and characterization of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. Biochem Soc Trans 1991;19:29(S).
32. Wharton TW. Adenographia. Translated by S. Freer. Oxford, U.K.: Oxford University Press, 1996:242-248.
33. Naughton BA, San Roman J, Liu K et al. Cells isolated from Wharton's jelly of thehuman umbilical cord develop a cartilage phenotype when treated with TGFβ in vitro. FASEB J 1997;11:A19.
34. Purchio AF, Naughton BA, Roman JS. Production of cartilage tissue using cells isolated from Wharton's Jelly. U.S. patent no. 5,919,702, 1999.
35. Mitchell KE, Weiss ML, Mitchell BM et al. Matrix cells from Wharton's jelly form neurons and glia. STEM CELLS 2003;21:50-60.
36. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. STEM CELLS 2003;21:105-110.
37. Kadner A, Hoerstrup SP, Tracy J et al. Human umbilical cord cells: a new cell source for cardiovascular tissue engineering. Ann Thorac Surg 2002;74:S1422-S1428.
38. Kadner A, Zund G, Maurus C et al. Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg 2004;25:635-641.
39. Chacko AW, Reynolds SRM. Architecture of distended and nondistended human umbilical cord tissues, with special reference to the arteries and veins. Carnegie Institution of Washington, Contributions to Embryology 1954;35:135-150.
40. Takechi K, Kuwabara Y, Mizuno M. Ultrastructural and immunohistochemical studies of Wharton's jelly umbilical cord cells. Placenta 1993;14:235-245.
41. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976;4:267-274.
42. Parker E, Shiga A, Davies JE. Growing human bone in vitro. In: JE Davies, ed., Bone Engineering. Toronto: EM Squared, 2000:63-77.
43. Kogler G, Sensken S, Airey JA et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004;200:123-135.
44. Kobayashi K, Kubota T, Aso T. Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alpha-smooth muscle actin. Early Hum Dev 1998;51:223-233.
45. Nayak RC, Berman AB, George KL et al. A monoclonal antibody (3G5)-defined ganglioside antigen is expressed on the cell surface of microvascular pericytes. J Exp Med 1988;167:1003-1015.
46. Schor AM, Allen TD, Canfield AE et al. Pericytes derived from the retinal microvasculature undergo calcification in vitro. J Cell Sci 1990;97:449-461.
47. Schor AM, Canfield AE, Sutton AB et al. Pericyte differentiation. Clin Orthop 1995;313:81-91.
48. Schor AM, Canfield AE. Osteogenic potential of vascular pericytes. In: JN Beresford, ME Owen, eds. Marrow Stromal Cell Culture. New York: Cambridge University Press, 1998:128-148.
49. Doherty MJ, Canfield AE. Gene expression during vascular pericyte differentiation. Crit Rev Eukaryot Gene Expr 1999;9:1-17.
50. Craig W, Kay R, Cutler RL et al. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177:1331-1342.
51. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615-2625.
52. Aubin JE. Bone stem cells. J Cell Biochem Suppl 1998;30-31:73-82.
53. Gimble JM, Robinson CE, Wu X et al. The function of adipocytes in the bone marrow stroma: an update. Bone 1996;19:421-428.
54. Cancedda R, Descalzi CF, Castagnola P. Chondrocyte differentiation. Int Rev Cytol 1995;159:265-358.
55. Caplan AI. The mesengenic process. Clin Plast Surg 1994;21:429-435.
56. Hovatta O, Mikkola M, Gertow K et al. A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum Reprod 2003;18:1404-1409.
57. Suva D, Garavaglia G, Menetrey J et al. Non-hematopoietichematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem stem cells. J Cell Physiol 2004;198:110-118.
58. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997;64:278-294.
59. Connolly JF. Injectable bone marrow preparations to stimulate osteogenic repair. Clin Orthop 1995;8-18.
60. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997;79:1699-1709.
61. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615-2625.
62. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003;10:228-241.
63. Baksh D, Davies JE, Zandstra PW. Adult human bone marrow-derived mesenchymal progenitor cells are capable of adhesion-independent survival and expansion. Exp Hematol 2003;31:723-732.
64. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
65. Saito T, Kuang JQ, Bittira B et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002;74:19-24.
66. Donovan PJ, Gearhart J. The end of the beginning for pluripotent stem cells. Nature 2001;414:92-97.